Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S. Dubash TD, et al. Among authors: bidard fc. Breast Cancer Res Treat. 2023 Aug;201(1):43-56. doi: 10.1007/s10549-023-06998-w. Epub 2023 Jun 15. Breast Cancer Res Treat. 2023. PMID: 37318638 Free PMC article.
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Darrigues L, Pierga JY, Bernard-Tessier A, Bièche I, Silveira AB, Michel M, Loirat D, Cottu P, Cabel L, Dubot C, Geiss R, Ricci F, Vincent-Salomon A, Proudhon C, Bidard FC. Darrigues L, et al. Among authors: bidard fc. Breast Cancer Res. 2021 Mar 6;23(1):31. doi: 10.1186/s13058-021-01411-0. Breast Cancer Res. 2021. PMID: 33676547 Free PMC article.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Bidard FC, et al. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584336 Free PMC article. Clinical Trial.
Reply to R. Nishihara et al.
Bidard FC, Kaklamani V, Bardia A. Bidard FC, et al. J Clin Oncol. 2022 Dec 20;40(36):4281-4282. doi: 10.1200/JCO.22.01768. Epub 2022 Sep 6. J Clin Oncol. 2022. PMID: 36067449 No abstract available.
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database.
Read SH, Quignot N, Kapso-Kapnang R, Comerford E, Zheng Y, Gainford C, Sasane M, Vataire AL, Delzongle L, Bidard FC. Read SH, et al. Among authors: bidard fc. Breast Cancer Res Treat. 2024 Apr;204(3):579-588. doi: 10.1007/s10549-023-07201-w. Epub 2024 Jan 11. Breast Cancer Res Treat. 2024. PMID: 38206533 Free PMC article.
202 results